Trial · NCT00784654
Results by group66
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 66
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent of Participants With Treatment Failures at End of The Randomized Withdrawal Period | Lisdexamfetamine Dimesylate (LDX)(Randomized Period) | 15.8 | percentage of participants | ||
| Percent of Participants With Treatment Failures at End of The Randomized Withdrawal Period | Placebo (Randomized Period) | 67.5 | percentage of participants | ||
| Change From Open-Label Baseline in The Attention Deficit Hyperactivity Disorder Rating Scale-Fourth Edition (ADHD-RS-IV) Total Score at Endpoint (Week-26) of The Open-label Period | Lisdexamfetamine Dimesylate (LDX)(Open-label Period) | -26.6 | Standard Deviation 11.39 | Scores on a scale | |
| Change From Randomized Withdrawal Baseline in The ADHD-RS-IV Total Score at Endpoint of The Randomized Withdrawal Period | Lisdexamfetamine Dimesylate (LDX)(Randomized Period) | 1.2 | Standard Error 1.09 | Scores on a scale | |
| Change From Randomized Withdrawal Baseline in The ADHD-RS-IV Total Score at Endpoint of The Randomized Withdrawal Period | Placebo (Randomized Period) | 13.8 | Standard Error 1.06 | Scores on a scale | |
| Percent of Participants With Clinical Global Impression - Severity of Illness (CGI-S) at Endpoint (Week-26) of The Open-label Period | Lisdexamfetamine Dimesylate (LDX)(Open-label Period) | Normal, not at all ill | 39.9 | percentage of participants | |
| Percent of Participants With Clinical Global Impression - Severity of Illness (CGI-S) at Endpoint (Week-26) of The Open-label Period | Lisdexamfetamine Dimesylate (LDX)(Open-label Period) | Borderline mentally ill | 46.5 | percentage of participants | |
| Percent of Participants With Clinical Global Impression - Severity of Illness (CGI-S) at Endpoint (Week-26) of The Open-label Period | Lisdexamfetamine Dimesylate (LDX)(Open-label Period) | Mildly ill | 1.5 | percentage of participants | |
| Percent of Participants With Clinical Global Impression - Severity of Illness (CGI-S) at Endpoint (Week-26) of The Open-label Period | Lisdexamfetamine Dimesylate (LDX)(Open-label Period) | Moderately ill | 6.6 | percentage of participants | |
| Percent of Participants With Clinical Global Impression - Severity of Illness (CGI-S) at Endpoint (Week-26) of The Open-label Period | Lisdexamfetamine Dimesylate (LDX)(Open-label Period) | Markedly ill | 4.5 | percentage of participants | |
| Percent of Participants With Clinical Global Impression - Severity of Illness (CGI-S) at Endpoint (Week-26) of The Open-label Period | Lisdexamfetamine Dimesylate (LDX)(Open-label Period) | Severely ill | 0.5 | percentage of participants | |
| Percent of Participants With Clinical Global Impression - Severity of Illness (CGI-S) at Endpoint (Week-26) of The Open-label Period | Lisdexamfetamine Dimesylate (LDX)(Open-label Period) | Among the most extremely ill | 0.5 | percentage of participants | |
| Percent of Participants With CGI-S at Open-label Baseline | Lisdexamfetamine Dimesylate (LDX)(Open-label Period) | Normal, not at all ill | 0 | percentage of participants | |
| Percent of Participants With CGI-S at Open-label Baseline | Lisdexamfetamine Dimesylate (LDX)(Open-label Period) | Borderline mentally ill | 0 | percentage of participants | |
| Percent of Participants With CGI-S at Open-label Baseline | Lisdexamfetamine Dimesylate (LDX)(Open-label Period) | Mildly ill | 1.5 | percentage of participants | |
| Percent of Participants With CGI-S at Open-label Baseline | Lisdexamfetamine Dimesylate (LDX)(Open-label Period) | Moderately ill | 27.2 | percentage of participants | |
| Percent of Participants With CGI-S at Open-label Baseline | Lisdexamfetamine Dimesylate (LDX)(Open-label Period) | Markedly ill | 50.2 | percentage of participants | |
| Percent of Participants With CGI-S at Open-label Baseline | Lisdexamfetamine Dimesylate (LDX)(Open-label Period) | Severely ill | 17.6 | percentage of participants | |
| Percent of Participants With CGI-S at Open-label Baseline | Lisdexamfetamine Dimesylate (LDX)(Open-label Period) | Among the most extremely ill | 3.4 | percentage of participants | |
| Percent of Participants With CGI-S at Endpoint of The Randomized Withdrawal Period, Last Observation Carried Forward (LOCF) | Lisdexamfetamine Dimesylate (LDX)(Randomized Period) | Normal, not at all ill | 40.0 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00784654/results